The condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018, the related condensed consolidated statements of income and condensed consolidated statements of comprehensive income for the three and nine months ended September 30, 2019 and 2018, and the related condensed consolidated statements of cash flow for the nine months ended September 30, 2019 and 2018 include the accounts of Amphenol Corporation and its subsidiaries (“Amphenol”, the “Company”, “we”, “our”, or “us”).
Prior to adoption, the Company evaluated Topic 842, including the initial review of any necessary changes to existing processes and systems that would be required to implement this standard, in order to determine its impact on our consolidated financial statements and related disclosures.
have a material impact on our Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2019 and our Condensed Consolidated Statements of Cash Flow for the nine months ended September 30, 2019, nor did it have any impact on our compliance with debt covenants.
On April 24, 2018, the Company’s Board of Directors authorized a stock repurchase program under which the Company may purchase up to $2,000.0 of the Company’s Common Stock during the three-year period ending April 24, 2021 (the “2018 Stock Repurchase Program”) in accordance with the requirements of Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
During the three and nine months ended September 30, 2019, the Company repurchased 1.7 million and 6.1 million shares of its Common Stock for $150.0 and $558.7, respectively, under the 2018 Stock Repurchase Program.
Of the total repurchases during the first nine months of 2019, 1.0 million shares, or $87.6, have been retained in Treasury stock; the remaining 5.1 million shares, or $471.1, have been retired by the Company.
The Company has not repurchased any additional shares of its Common Stock from October 1, 2019 to October 22, 2019, and has remaining authorization to purchase up to $888.1 of its Common Stock under the 2018 Stock Repurchase Program.
These repurchases in the first quarter of 2018, coupled with the Company’s repurchase of 3.5 million shares of its Common Stock for $298.2 under the 2018 Stock Repurchase Program during the six months ended September 30, 2018, resulted in total repurchases of 7.7 million shares for $680.2 during the nine months ended September 30, 2018.
For the three months ended September 30, 2019 and 2018, the Company’s income before income taxes was reduced for stock-based compensation expense of $16.6 and $14.4, respectively.
A committee of the Company’s Board of Directors has been authorized to grant stock options pursuant to the 2017 Employee Option Plan.
As of September 30, 2019, there were 10,943,910 shares of Common Stock available for the granting of additional stock options under the 2017 Employee Option Plan.
The grant-date fair value of each option grant under the 2009 Employee Option Plan, the 2017 Employee Option Plan and the 2004 Directors Option Plan is estimated using the Black-Scholes option pricing model.
The grant-date fair value of each share grant is determined based on the closing share price of the Company’s Common Stock on the date of the grant.
As of September 30, 2019, the number of restricted shares available for grant under the 2012 Directors Restricted Stock Plan was 94,846.
This voluntary cash contribution made in the first quarter of 2018 was reflected as cash used in operating activities within Net change in accrued pension and postretirement benefits in the Condensed Consolidated Statements of Cash Flow.
During the nine months ended September 30, 2019 and 2018, the Company provided matching contributions to the U.S. defined contribution plans of approximately $9.8 and $6.2, respectively.
The contingent consideration is payable in 2020 and recorded in Other accrued expenses on the accompanying Condensed Consolidated Balance Sheets as of September 30, 2019.